Abstracts tagged "Cohort Study"

Abstract Number: 2686 • ACR Convergence 2025
Impact of autoimmunity, disease activity and treatment on the time course of bone density, microstructure and biomechanics in inflammatory arthritis.
Koray Tascilar¹, Alp Temiz¹, Filippo Fagni², Arnd Kleyer³, Louis Schuster¹, Stephan Kemenes¹, Sara Bayat¹, David Simon⁴ and Georg Schett⁵, ¹Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Germany, ²Department of Medicine ³ - Rheumatology and Immunology, Friedrich-Alexander-Universität Erlangen-Nürnberg and University Hospital Erlangen, Erlangen, Bayern, Germany, ³Charite Universitätsmedizin Berlin, Erlangen, Bayern, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany; Deutsches Rheuma-Forschungszentrum Berlin, Berlin, Germany, Berlin, Germany, ⁵Uniklinikum Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Germany, Erlangen, Germany
Background/Purpose: RA and PsA follow different pathomechanisms and incur disease-specific erosive and osteoproliferative bone changes. We used data from a large cohort of RA and…
Abstract Number: 2403 • ACR Convergence 2025
Differential Risk of Inpatient Admissions Among SLE Subgroups: A Population-Based Analysis
Jaime Flores-Gouyonnet¹, Erika Navarro-Mendoza¹, Mario Bautista-Vargas¹, Ali Ardekani¹, Maria Cuellar-Gutierrez¹, Gabriel Figueroa-Parra², Mariana Gonzalez-Treviño³, Alain Sanchez-Rodriguez⁴, Andrew C. Hanson¹, Cassondra Hulshizer⁵, Cynthia Crowson⁶ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, Mexico, ³Vanderbilt University Medical Center, Nashville, TN, ⁴ABC Medical Center, Ciudad de México, Federal District, Mexico, ⁵Mayo Clinic, Rochester, ⁶Mayo Clinic, Stewartvillle, MN
Background/Purpose: SLE is clinically heterogeneous and associated with increased hospitalizations. However, it remains unclear which patient subgroups drive this excess in unplanned healthcare use. We…
Abstract Number: 2087 • ACR Convergence 2025
Does Carbamazepine Impact Risk of Developing Osteoarthritis? Results of a Real-World Data Analysis
Erfan Afshar¹ and Andrew Long², ¹VCUSOM, Richmond, VA, ²Virginia Commonwealth University Health System, Midlothian, VA
Background/Purpose: Carbamazepine has shown chondroprotective effects in OA animal models by modulating Nav1.7 channels. This study aimed to examine the association between Carbamazepine use and…
Abstract Number: 1898 • ACR Convergence 2025
Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison
Evelyn Fagan¹, Joseph McGrath¹, Calla Sullivan¹, Mackenzie Kilton¹, Kaeli Samson², Kaleb Michaud³ and Sarah Lonowski¹, ¹University of Nebraska Medical Center Department of Dermatology, Omaha, NE, ²University of Nebraska Medical Center Department of Biostatistics, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Ensuring that data registries include a representative sample is crucial for obtaining findings that can be generalized to the larger population. This comparative observational…
Abstract Number: 1552 • ACR Convergence 2025
Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
Zahi Touma¹, Ian Bruce², Richard Furie³, Eric Morand⁴, Raj Tummala⁵, Shelly Chandran⁶, Gabriel Abreu⁷, Jacob Knagenhjelm⁷, Cathy Emmas⁸, Lyra Agustin⁸, Alessandra Venerus⁹, Tarana Mehdikhanova¹⁰, Zheyuan Yang¹⁰ and Miina Waratani⁸, ¹University of Toronto, Toronto, ON, Canada, ²Centre for Public Health, Faculty of Medicine, Health and Life Sciences, Queen's University, Belfast, Manchester, United Kingdom, ³Division of Rheumatology, Northwell Health, Great Neck, NY, ⁴Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ⁵AstraZeneca, BioPharmaceuticals R&D, Gaithersburg, Gaithersburg, MD, ⁶AstraZeneca, Medical & Scientific Affairs, R&I, Mississauga, ON, Canada, ⁷AstraZeneca, BioPharmaceuticals R&D, Gothenburg, Sweden, ⁸AstraZeneca, BioPharmaceuticals Medical, Cambridge, United Kingdom, ⁹IQVIA, EMEA Real World Methods and Evidence Generation, Milan, Italy, ¹⁰IQVIA, EMEA Real World Methods and Evidence Generation, London, United Kingdom
Background/Purpose: Patients with systemic lupus erythematosus (SLE) can develop cardiovascular (CV) damage (angina, myocardial infarction, ventricular dysfunction, valvular disease, or pericarditis for 6 months/pericardiectomy) particularly…
Abstract Number: 1386 • ACR Convergence 2025
Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
Hoang Nguyen¹, Philip Moresco², Antoine Chiu², Asha Patnaik³ and Peter Gorevic⁴, ¹Stony Brook University-Renaissance School of Medicine- Department of Rheumatology, Jamaica, NY, ²Stony Brook University -Renaissance School of Medicine, Stony Brook, NY, ³Stony Brook University Hospital, Stony Brook, NY, ⁴Stony Brook University, Stony Brook, NY
Background/Purpose: -Sjogren’s syndrome (SS) is a chronic autoimmune disorder, defined by keratoconjunctivitis sicca (KCS), specific serologies, and a significant risk of extra-exocrine disease manifestations and…
Abstract Number: 1100 • ACR Convergence 2025
Associations Between Pre-Existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
Gregory Challener¹, Chen Wang², David Gritsch², Ilana Usiskin³, Zandra E. Walton¹, Minna Kohler⁴, Hyon K. Choi⁵ and Jeffrey Sparks⁶, ¹Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, ²Harvard T.H. Chan School of Public Health, Boston, ³Division of Rheumatology, Inflammation, and Immunity, Department of Medicine, Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵MASSACHUSETTS GENERAL HOSPITAL, Lexington, MA, ⁶Brigham and Women's Hospital, Boston, MA
Background/Purpose: Chimeric antigen receptor (CAR) T cell therapy is being investigated to treat individuals with autoimmune diseases. Data regarding the safety of CAR T cell…
Abstract Number: 0561 • ACR Convergence 2025
Patient Characteristics and Treatment Patterns of Traditional and Advanced Therapies Prior to First Secukinumab Intravenous (IV) Administration in Patients with Spondyloarthritis (SpA) in US Real-World Clinical Settings
Alan Kivitz¹, Linda Grinnell-Merrick², Tim Nguyen², Ariane Faucher³, Riley Taiji³, Francis Vekeman³ and Atul Singhal⁴, ¹Altoona Center for Clinical Research, Duncansville, PA, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³STATLOG, Inc, Montreal, QC, Canada, ⁴SouthWest Arthritis Research Group, Mesquite, TX
Background/Purpose: Since most approved biologics are administered subcutaneously, there is a need for alternate routes of delivery to treat patients with SpA. Secukinumab is an…
Abstract Number: 0407 • ACR Convergence 2025
The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort
Ilaria Maccora¹, Margaret Chang², Sheila Angeles-Han³, Andrea Taddio⁴, Lampros Fotis⁵, Cinzia de Libero⁶, Madison Mangin⁷, Alexandra Duell⁸, Marco Gabrielli⁹, Kyveli Chiotopoulou⁵, Lillian Sutton¹⁰, Virginia Miraldi Utz⁸ and Gabriele Simonini¹¹, ¹Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, ²Boston Children's Hospital, Boston, MA, ³Cincinnati Children's Hospital, Cincinnati, OH, ⁴Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, ⁵Division of Pediatric Rheumatology, Department of Pediatrics, ATTIKON General Hospital, National and Kapodistrian University of Athens, Greece, Athene, Greece, ⁶Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, Florence, Italy, ⁷Boston Children's Hospital, St Simons Island, GA, ⁸Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁹University of Trieste, Trieste, Italy, Trieste, Italy, ¹⁰Division of Immunology, Boston Children’s Hospital, Boston, MA, USA, Boston, ¹¹Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy
Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…
Abstract Number: 0165 • ACR Convergence 2025
Per-Protocol Analysis of the Effectiveness of GLP1 Agonists Against SGLT2 Inhibitors on Osteoarthritis Outcomes
Nene Ukonu¹, David Felson², Michael LaValley³ and S. Reza Jafarzadeh⁴, ¹Boston University School of Public Health, Boston, MA, ²Boston University, Boston, MA, ³Boston University School of Public Health, Arlington, MA, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA
Background/Purpose: Anti-diabetic medications often have effects on other conditions. GLP1 agonists (GLP1a) have shown protective effects on OA outcomes in trials and short-term trial emulations,…
Abstract Number: 2683 • ACR Convergence 2025
Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Stevie Barry¹, Katie McMenamin², Austin Wheeler³, Bryant England³, Grant Cannon⁴, Brian Sauer⁵, Gary Kunkel⁶, Katherine Wysham⁷, Beth Wallace⁸, Andreas Reimold⁹, Gail Kerr¹⁰, Isaac Smith¹¹, John Richards¹², Iris Lee¹³, Rui Xiao¹, Sylvanus Toikumo¹⁴, Henry Kranzler¹⁴, Rachel Kember¹⁴, Scott Damrauer¹⁴, Michael Levin¹⁴, Michael George¹, Ted Mikuls³, Joshua Baker¹ and Thomas Riley¹, ¹University of Pennsylvania, Philadelphia, PA, ²Boston Medical Center, Boston, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴University of Utah and Salt Lake City VA, Salt Lake City, UT, ⁵Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁶University of Utah and George E Wahlen VAMC, Salt Lake City, UT, ⁷VA PUGET SOUND/UNIVERSITY OF WASHINGTON, Seattle, WA, ⁸Michigan Medicine, VA Ann Arbor Healthcare System, Ann Arbor, MI, ⁹Dallas VA Medical Center, Dallas, TX, ¹⁰Washington DC VAMC/Georgetown and Howard Universities, Washington, DC, ¹¹Duke University Hospital, Durham, NC, ¹²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, ¹³Washington University in St Louis, Saint Louis, MO, ¹⁴University of Pennsylvania / Corporal Michael J. Crescenz VAMC, Philadelphia, PA
Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…
Abstract Number: 2394 • ACR Convergence 2025
Impact of Immunosuppressive Regimens on Major Cardiac Events in Patients with Systemic Lupus Erythematosus (SLE): A Survival Analysis
Emily Cosentino¹, Melissa Akselrad², Niurka Liranzo Tejera², Christine Lenchur², Takemichi Matsui², Adal Abonamah², Priscilla Abate Namnum¹, Olga Marushchak², Martin John³, Sophia Lutgen⁴, Celestine He⁵, Boluwatito Oladeinde⁶, Harleen Sidhu⁷ and Chrisanna Dobrowolski⁵, ¹Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, ²Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, ³Icahn School of Medicine at Mount Sinai, New York, ⁴Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York City, NY, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Icahn School of Medicine, New York, NY, ⁷Icahn School of Medicine at Mount Sinai/NYC H+H- Elmhurst, Queens, NY, Rego Park, NY
Background/Purpose: Cardiovascular events are a significant source of morbidity and mortality in SLE patients, occurring more frequently than in the general population owing to immune…
Abstract Number: 2080 • ACR Convergence 2025
Foot laterality does not modify outcome of knee and/or hip osteoarthritis
Simon Fondin¹, Armand Eyraud¹, Estelle Nkonda¹, Anne-Christine Rat², Bruno Fautrel³, SELLAM JEREMIE⁴, Christian Roux⁵, Jacques Pouchot⁶, Joel Coste⁷, Francis Guillemin⁸ and Alain SARAUX⁹, ¹Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, ²Caen University hospital, UMR ¹⁰⁷⁵ Caen normandy university, Caen, France, ³Sorbonne Université - APHP, Department of Rheumatology, Hôpital Pitié-Salpêtrière, Inserm UMRS ¹¹³⁶-⁵, PARIS, France, Paris, France, ⁴Sorbonne Université, Inserm, Centre de Recherche Saint-Antoine, CRSA, F-⁷⁵⁰¹² Paris, France, /Rheumatology Department, AP-HP Saint-Antoine Hospital, ¹⁸⁴, rue du Faubourg Saint-Antoine, ⁷⁵⁰¹², Paris, France., Paris, France, ⁵CHU Nice, Nice, France, ⁶AP-HP, Rueil Malmaison, France, ⁷APHP, Paris, France, ⁸CHU Nancy, Nancy, France, ⁹CHU Brest, Brest, France
Background/Purpose: Hip and knee osteoarthritis (OA) are among the leading causes of global disability. Global OA is more prevalent on the right side. This discordance…
Abstract Number: 1879 • ACR Convergence 2025
Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study
Ayema Haque, Ana Salas, Bruna Diniz, Harshank Patel and Philip Kroth, Western Michigan University School of Medicine, Kalamazoo, MI
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disorder affecting up to 30% of psoriasis patients and is associated with increased infection risk. This…
Abstract Number: 1549 • ACR Convergence 2025
Improvement in Joint Activity in Adults with Systemic Lupus Erythematosus Treated with Anifrolumab: Results from a Real-World Cohort
Vasileios Kyttaris¹, Dan Persons², Gelareh Atefi³ and Mawuena Binka⁴, ¹Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA, ²Trio Health, Louisville, CO, ³AstraZeneca, Wilmington, DE, ⁴Former Employee of AstraZeneca, Wilmington, DE
Background/Purpose: Inflammatory arthritis is a cardinal manifestation of systemic lupus erythematosus (SLE), limiting joint mobility and adversely affecting quality of life.1 Joint activity in SLE…

1
2
3
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].